[go: up one dir, main page]

WO2006025329A1 - Agent antitumoral - Google Patents

Agent antitumoral Download PDF

Info

Publication number
WO2006025329A1
WO2006025329A1 PCT/JP2005/015664 JP2005015664W WO2006025329A1 WO 2006025329 A1 WO2006025329 A1 WO 2006025329A1 JP 2005015664 W JP2005015664 W JP 2005015664W WO 2006025329 A1 WO2006025329 A1 WO 2006025329A1
Authority
WO
WIPO (PCT)
Prior art keywords
present
shimeji
hon
extract
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/015664
Other languages
English (en)
Japanese (ja)
Inventor
Shigetoshi Mizutani
Yuka Hirota
Makiko Naka
Mayu Hashimoto
Takashi Kawai
Takeshi Sakai
Ikunoshin Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Priority to JP2006532676A priority Critical patent/JPWO2006025329A1/ja
Publication of WO2006025329A1 publication Critical patent/WO2006025329A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof

Definitions

  • the present invention relates to an antitumor agent using hon-shimeji (Lyophyllum shimeji), and a medicine, food or feed containing the same.
  • Patent Document 1 Japanese Patent Laid-Open No. 5-306233
  • Patent Document 2 International Publication No. 01Z51070 Pamphlet
  • Patent Document 3 Japanese Patent Laid-Open No. 2000-103752
  • Patent Document 4 JP-A-11-302191
  • Non-patent literature l Chem Pharm Bull, 36 (5), 1819-1827, 1988
  • Non-patent literature 2 Chem Pharm Bull, 35 (6), 2453-2458, 1987
  • Non-Patent Document 3 Jpn J Cancer Res (Gann), 76, 130-136, 1985
  • An object of the present invention is to provide an antitumor agent exhibiting an excellent effect orally, and a medicine, food or feed containing the same.
  • the first invention of the present invention is characterized by containing, as an active ingredient, at least one selected from the group consisting of honshimeji (Lyophyllum shimeji) and processed products thereof. It relates to an antitumor agent.
  • honshimeji Liphyllum shimeji
  • processed hon-shimeji mushroom include dry powder, extract or extraction residue.
  • a second invention of the present invention relates to a pharmaceutical comprising the antitumor agent of the first invention of the present invention.
  • a third invention of the present invention relates to a food or feed for treating or preventing a tumor characterized by containing the antitumor agent of the first invention of the present invention.
  • a fourth invention of the present invention relates to a method for treating a tumor, comprising administering to a subject at least one selected from the group consisting of an effective amount of hon-shimeji mushroom and a processed product thereof.
  • a fifth invention of the present invention relates to at least one use selected from the group consisting of hon-shimeji mushroom and its treated product for the production of the antitumor agent of the first invention of the present invention.
  • An orally effective antitumor agent characterized by containing at least one selected from the group of hon-shimeji mushroom and its processed product strength as an active ingredient is provided. Since the antitumor agent of the present invention is derived from edible mushrooms, it is less likely to cause side effects. Therefore, the antitumor agent is useful as a medicament, food or feed for treating or preventing tumors.
  • Honshimeji is occurring in nature! / In the fall, a lot of scallops occur in the Quercus serrata forest. For a long time, it has been said to be “scented squeeze taste shimeji” and is said to be a representative of the delicious taste. It is said to be widely distributed in East Asia including Japan. Honshimeji has been difficult to cultivate in the past, but recently it has been reported that artificial culturing has become possible (for example, JP 2000-106752, JP 2001-120059). This makes it possible to harvest mushrooms stably throughout the year regardless of the season. That is, honshimeji serving as a raw material for the active ingredient of the present invention can be easily obtained and used as a raw material for pharmaceuticals, foods or feeds.
  • the strain used as hon-shimeji may be a natural or artificially grown product. July 13, 1999;) :: Lyophyllum shimeji LaOl-20 (FERM P-16841, deposit date: June 16, 1998) All of the above strains have been deposited with the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (1st, 1st, 1st, Tsukuba, Higashi, Ibaraki 305-8566, Japan).
  • hon-shimeji means those classified as Lyophyllum shimeji in terms of taxonomy.
  • the power that has been circulated as “Yamabiko Honshimeji” or “Honjimeji” is a categorized as “Hypsizigus marmoreusj” (previously classified as Lyophyllu mulmarium).
  • fruit bodies or mycelia thereof can be used.
  • the fruit bodies can be raw or dried fruit bodies dried by heating, sun drying, freeze drying, etc.
  • the fruit body can be used as a stock or crushed.
  • live or dried mycelium obtained by culturing inoculum in a medium containing a carbon source and a nitrogen source can be used, and a dried one is easy to use.
  • the treated product is not particularly limited as long as it is obtained by subjecting hon-shimeji to artificial treatment.
  • a dry powder, an extract, an extraction residue, a heat-treated product, a pulverized product, a juice examples include crushed products, dried products, frozen products, enzyme-treated products, chemical-treated products, and processed products obtained by combining these treatment processes.
  • dry powder, extract, and extraction residue are exemplified.
  • the form of the treated product there are no particular limitations on the form of the treated product as long as it can be used as the active ingredient of the present invention.
  • a raw material of these processed products either a fruit body or a mycelium of Honshimeji can be used as a raw material of these processed products.
  • the production method is not particularly limited.
  • the raw material of the treated product as described above is sun-dried, freeze-dried, dry heat dried
  • the dried product obtained by performing a known drying process such as air drying can be obtained by pulverizing with various pulverizing mixers such as a bead mill, a milling blender, and a homogenizer.
  • an extract refers to a thread and product obtained through a process of performing an extraction operation using an extraction solvent.
  • Specific examples include a water extract, a hot water extract, an ethanol extract, an ethyl acetate extract, a methanol extract, an acetone extract, a hexane extract and the like.
  • a hot water extract is used.
  • An ethyl acetate extract is preferably used.
  • Extraction can be performed as follows by a known extraction method. For example, after the raw material is pulverized or shredded, extraction can be performed batchwise or continuously using a solvent.
  • the above-mentioned dry powder of hon-shimeji mushroom, and the following chemical-treated or enzyme-treated product of hon-shimeji mushroom can be used as the raw material.
  • the extraction solvent for obtaining the extract is not particularly limited. Water, hexane, chloroform, alcohols such as ethanol, methanol, isopropyl alcohol, ketones such as acetone and methyl ethyl ketone, and hydrophilic or lipophilic solvents such as methyl acetate and ethyl acetate. If desired, it can be used alone or as appropriate as a mixed solution.
  • the amount of the extraction solvent may be determined as appropriate, but usually 0.1 to LOO times the amount of extraction solvent is preferably used relative to the weight of the raw material used in the extraction operation.
  • the extraction temperature may be appropriately determined according to the purpose, but in the case of water extraction, it is usually preferably 4 to 130 ° C, more preferably 25 to 100 ° C. In this specification, water extraction at an extraction temperature of 50 ° C or higher is called hot water extraction, and an extract obtained by hot water extraction is called hot water extract. Further, when ethanol is contained in the solvent, the range of 4 to 60 ° C is preferable.
  • the extraction time may be determined in consideration of the extraction efficiency.
  • the raw material, the extraction solvent, and the extraction temperature are set to be preferably in the range of several seconds to several days, more preferably 5 minutes to 24 hours. Is preferred.
  • the pressure at the time of extraction can be appropriately determined as desired without particular limitation.
  • the extraction operation can be performed by selecting conditions as desired, for example, under normal pressure, under pressure, or under reduced pressure by suction filtration or the like.
  • the extraction operation may be performed with stirring or standing, for example, and may be repeated several times as necessary.
  • an extract of hon-shimeji mushroom used in the present invention hereinafter sometimes referred to as the extract of the present invention
  • the extract can be treated by filtration, centrifugation, concentration, ultrafiltration, molecular sieving, etc.
  • an extract in which the target component having antitumor activity is concentrated is concentrated.
  • the antitumor action of the extract or concentrated extract can be measured according to the method described in Example 2 described later.
  • two or more extracts obtained by different extraction methods can be used in combination.
  • the extract of the present invention thus obtained can be subjected to treatments such as vacuum concentration, sterilization, freeze drying, spray drying and the like to remove the extraction solvent and obtain a dried hon-shimeji extract.
  • an extract obtained by extracting the extraction residue with a different solvent can also be used as the extract of the present invention.
  • an ethyl acetate extract of a hot water extraction residue can be used.
  • the fraction obtained by fractionating the extract of the present invention by a known method and the fraction obtained by repeating the fractionation operation a plurality of times are also the extract of the present invention.
  • the fractionation means include extraction, fractional precipitation, column chromatography, thin layer chromatography and the like.
  • the active ingredient can also be isolated by further purifying the obtained fraction using the antitumor action as an index. Those components are also included in the active ingredients of the present invention.
  • the extraction residue means a residue obtained after extraction as described above, and these can also be used as an active ingredient of the present invention.
  • hon-shimeji hot water extraction residue obtained by the process as described in Example 1 is exemplified.
  • a heat-treated product of hon-shimeji is used as the treated product of the present invention
  • the production method is not particularly limited.
  • a dry powder of hon-shimeji is suspended in water and 50-120. C, preferably 60 to 110 ° C, and more preferably 70 to 100 ° C.
  • the heating time There are no particular limitations on the heating time, but examples include a range of several seconds to several days, more preferably 5 minutes to 24 hours.
  • hon-shimeji mushroom juice when used as the processed product of the present invention, the production method thereof can be carried out in the same manner as the known method of squeezing plants, and is not particularly limited.
  • a method using a squeezing machine such as a clew type, a gear type, a cutter type or a juicer can be used.
  • the raw material can be shredded or ground and then squeezed with the above-mentioned juicer or cloth to obtain a juice.
  • the crushed material is a material obtained by crushing hon-shimeji mushroom used as a raw material for the active ingredient, and generally has a tissue piece larger than the pulverized material.
  • a crusher is used.
  • the dried product can be obtained by drying a hon-shimeji mushroom used as a raw material of an active ingredient by sun-drying and performing a known drying treatment such as freeze drying, dry heat drying, hot air drying or the like.
  • the frozen product is not particularly limited as long as it is obtained by a known freezing method.
  • a frozen product obtained by the method described in JP-A-6-284858 or JP-A-2000-69927 can be used. .
  • the chemically treated product is not particularly limited, but is obtained by subjecting hon-shimeji to acid treatment, alkali treatment, oxidation treatment, reduction treatment, osmotic pressure treatment, etc., for example, hydrochloric acid, sulfuric acid, Honshimeji is soaked in an aqueous solution containing an inorganic or organic acid such as nitric acid, citrate, or acetic acid, or an inorganic base or organic base such as sodium hydroxide, potassium hydroxide, or ammonia, and heated as necessary.
  • an inorganic or organic acid such as nitric acid, citrate, or acetic acid
  • an inorganic base or organic base such as sodium hydroxide, potassium hydroxide, or ammonia
  • the enzyme-treated product is, for example, an enzyme-treated product such as pectinase, cellulase, xylanase, amylase, mannanase, gnorecosidase, hemicenolase, chitinase, a-and-j8-darc mouth nidase, a-and-j8-dalcanase, etc.
  • An enzyme reaction product for example, a fermented product obtained by the above-mentioned method can be produced, for example, by reacting hon-shimeji mushroom with the above enzyme in an appropriate buffer.
  • Enzyme-treated products include all those derived from hon-shimeji that have been subjected to the enzyme treatment as described above.
  • the active ingredient of the present invention is not particularly toxic as described later. In addition, the possibility of side effects is low. Therefore, the antitumor activity can be expressed safely and appropriately. Therefore, the antitumor agent of the present invention comprising the active ingredient and the medicine, food or feed containing the same are effective for treating or preventing tumors.
  • the disease targeted by the antitumor agent is not particularly limited as long as it is a disease that requires an antitumor action for treatment, and examples thereof include all malignant tumors.
  • examples of the disease include gastric cancer, colon cancer, esophageal cancer, skin cancer, uterine cancer, prostate cancer, bladder cancer and lung cancer.
  • malignant tumors of hematopoietic organs such as leukemia can also be targeted for the antitumor agent of the present invention.
  • the antitumor agent of the present invention exhibits remarkable antitumor activity against sarcoma cells, and thus occurs in tissues other than epithelium, such as muscle, vascular, cartilage, bone, hematopoietic tissue, nerves, etc. Tumors, so-called sarcomas, are also subject to the antitumor agent of the present invention.
  • the antitumor agent of the present invention is characterized in that it contains at least one selected from the group consisting of hon-shimeji mushroom and its processed product as an active ingredient.
  • at least one selected from the group consisting of the above-mentioned hon-shimeji mushroom and its processing power may be referred to as an active ingredient of the present invention.
  • the antitumor agent of the present invention may be the active ingredient itself or a composition containing the active ingredient. Examples of the antitumor agent of the present invention include those prepared by combining the active ingredient according to the present invention with a known carrier. Further, in the antitumor agent of the present invention, the active ingredient can be used for other components that can be used for the same purpose as the active ingredient, for example, known antitumor agents Can be blended or used together.
  • the production of the antitumor agent of the present invention is usually carried out by blending the active ingredient with a pharmaceutically acceptable liquid or solid carrier, and if desired, a solvent, a dispersant, an emulsifier, a buffer.
  • the carrier can be selected depending on the dosage form and dosage form of the antitumor agent of the present invention.
  • an oral preparation comprising a solid composition
  • it can be a tablet, pill, capsule, powder, fine granule, granule, etc., for example, starch, lactose, sucrose, mannitol, carboxy Methyl cellulose, corn starch, inorganic salts, etc. are used as carriers.
  • a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a corrigent, a coloring agent, a fragrance and the like can be further added.
  • a sugar coating such as sucrose, gelatin or hydroxypropylcellulose, or a film of a gastric or enteric substance, if desired.
  • a sugar coating such as sucrose, gelatin or hydroxypropylcellulose
  • a film of a gastric or enteric substance if desired.
  • an oral preparation comprising a liquid composition
  • it can be a pharmacologically acceptable emulsion, solution, suspension, syrup, etc.
  • purified water, ethanol, etc. are used as a carrier. Is done.
  • adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, preservatives and the like may be added.
  • a parenteral preparation when used, distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil are used according to a conventional method, and the active ingredient of the present invention is used as a diluent. It can be prepared by dissolving or suspending in corn oil, propylene glycol, polyethylene glycol or the like, and adding a bactericidal agent, stabilizer, tonicity agent, soothing agent, etc., if necessary. In addition, a solid composition can be produced and used by dissolving in sterile water or a sterilized solvent for injection before use.
  • External preparations include solid, semi-solid or liquid preparations for transdermal administration or transmucosal (intraoral or intranasal) administration. Also included are suppositories and the like. For example, emulsions, emulsions such as mouth lotions, tinctures for external use, liquid preparations such as liquids for transmucosal administration, oily Ointments such as ointments and hydrophilic ointments, patches for transdermal administration or transmucosal administration such as films, tapes, and nops can be used.
  • each of the above-mentioned various preparations can be appropriately produced by a conventional method using a known pharmaceutical carrier or the like.
  • the content of the active ingredient in a potent formulation is not particularly limited as long as the active ingredient can be administered within the dosage range described below, taking into consideration its administration form, administration method and the like. Absent.
  • the content of the active ingredient in the antitumor agent of the present invention is about 0.1 to about LOO% by weight.
  • the antitumor agent of the present invention is administered by an appropriate administration route according to the preparation form.
  • the administration method is not particularly limited, and can be internal, external, and injection.
  • An injection can be administered, for example, intravenously, intramuscularly, subcutaneously, or intradermally.
  • a suppository should be administered by an appropriate administration method.
  • the dose as the antitumor agent of the present invention is appropriately set depending on the preparation form, administration method, purpose of use, and age, weight, and symptom of the patient to whom the antitumor agent is administered, and is not constant.
  • the daily dose for an adult is 150 g to 1 kgZkg body weight, preferably 150 g to 500 gZkg body weight, more preferably 1.5 mg, in terms of the dry weight of hon-shimeji, an active ingredient contained in the preparation.
  • ⁇ 500 gZkg body weight, more preferably 1.5 mg to 200 gZkg body weight, even more preferably 15 mg to 150 gZkg body weight, even more preferably 15 mg ⁇ : LOOg / kg body weight is desirable.
  • the dry weight conversion of the active ingredient hon-shimeji mushroom contained in the preparation means, for example, when the active ingredient is an extract, the amount of the extract contained in the preparation is the dry weight of the hon-shimeji mushroom used as a raw material. Says the value expressed. Since the dosage varies depending on various conditions, an amount smaller than the above dosage may be sufficient, or it may be necessary to exceed the range. Administration may be carried out once or divided into several times within a desired dosage range within one day. The administration period is also arbitrary. Further, the antitumor agent of the present invention can be administered orally as it is, or it can be added to any food and regularly ingested.
  • the production method, dosage form, active ingredient content, dose, administration route, administration method and the like of the medicament of the present invention are the same as those of the antitumor agent. Since the medicament of the present invention contains the antitumor agent, it can safely and appropriately exhibit antitumor activity.
  • the term "containing" in the food or feed of the present invention means inclusion, addition and / or dilution.
  • “containing” means that the active ingredient used in the present invention is contained in food or feed
  • additional means that the active ingredient used in the present invention is added to the raw material of food or feed.
  • “dilution” means that when an ingredient for food or feed is added to the active ingredient used in the present invention, the aspect is changed.
  • the food production method of the present invention is not particularly limited! For example, formulation, cooking, power! ] And the like can be produced by the production method of ordinary foods, and the obtained food contains the active ingredient according to the present invention! I'm good!
  • the food of the present invention is not particularly limited.
  • processed food products eg, processed flour products, starch cake products, premix processed products, rice cakes, macaroni products, bread products, Vietnamesemp, buckwheat, rice bran, rice noodles, harsame, packaging rice cake, etc.
  • processed oils and fats eg, plastic oil, sesame oil, salad oil, mayonnaise, dressing, etc.
  • processed soybeans eg, tofu, miso, Natto, etc.
  • processed meat products eg, ham, bacon, pressed ham, sausage, etc.
  • fishery products eg, frozen groundnut, power boiled rice, chikuwa, hampen, deep-fried sweet potato, tsunami, streaks, fish ham, sausage, Bonito, processed egg products, canned fish, tsukudani, etc.
  • dairy products eg, raw milk, cream, yogurt, butter, cheese, condensed milk, powdered milk, ice cream, etc.
  • vegetables' fruit calories
  • the active ingredient is contained alone or in plural, added and Z or diluted, and the content corresponds to a necessary amount for developing anti-tumor activity
  • the shape includes tablets, granules, capsules and the like that can be taken orally. Moreover, it can also be set as the health food which concentrated the active ingredient by adding glycerol etc. to the said active ingredient.
  • a product obtained by immersing the fruit body of Honshimeji used in the present invention in drinking alcohol is used as it is or in a known method for producing an alcoholic beverage. It can be used for drinking as an alcoholic beverage obtained in a similar manner.
  • processed products of hon-shimeji fruit bodies or mycelium used as an active ingredient in the present invention for example, pulverized products and crushed products formed into tablets, granules, etc. according to known methods are also used. Included in the food product of the invention.
  • the content of the active ingredient in the food of the present invention is not particularly limited, and can be appropriately selected from the viewpoint of its sensory and activity expression, but in 100% by weight of the food, 0.01% by weight or more of the active ingredient.
  • the food of the present invention is preferably a human (in terms of dry weight of hon-shimeji, an active ingredient contained therein)
  • the body weight, more preferably 15 mg to 150 gZkg body weight, and even more preferably 15 mg to: LOOgZkg body weight may be taken.
  • the dry weight conversion of the active ingredient hon-shimeji mushroom contained in food means, for example, when the active ingredient is an extract, the amount of extract contained in the food is expressed as the dry weight of hon-shimeji mushroom used as a raw material.
  • the amount of intake varies depending on various conditions, such as the type of extraction solvent and the amount of solvent used, so an amount smaller than the above intake amount may be sufficient, or it may be necessary to exceed the range. is there.
  • the food of the present invention is a food for treating or preventing tumors, and is particularly useful in maintaining the homeostasis of the living body by ingesting and eating the food of the present invention.
  • the food may be, for example, a health food (a food for specified health use) with a label indicating that it is used for manifestation of a desired effect due to antitumor activity.
  • the present invention provides a biological feed comprising the active ingredient, and as another aspect, the active ingredient is administered to the living organism. It also provides a method of rearing. Moreover, as another aspect of the present invention, there is provided a biological breeding agent comprising the above-mentioned active ingredient.
  • “containing” means the above-mentioned inclusion, addition and / or dilution.
  • the living organisms are, for example, farm animals, pet animals, etc.
  • the farm animals include domestic animals such as horses, bushes, pigs, hidges, goats, ratadas, llamas, mice, rats
  • Examples include laboratory animals such as guinea pigs and rabbits, poultry such as tiger birds, ducks, turkeys and eagle birds, fish, crustaceans and shellfish
  • examples of pet animals include dogs and cats.
  • feed include feed for tumor treatment and Z or prevention.
  • biological breeding agents include soaking agents, feed additives, and beverage additives.
  • the active ingredient used in the feed of the present invention is usually the active ingredient in 100% by weight of the feed in terms of dry weight of hon-shimeji mushroom when the active ingredient is a dry powder of the fruit body of hon-shimeji mushroom. .01 wt% or more, preferably 0.1 to 95 wt%, more preferably 1 to 90 wt%, and the feed of the present invention is preferably converted into dry weight of hon-shimeji as an active ingredient contained therein.
  • the target organism is 150 g to 1 kgZkg body weight per day, more preferably 150 / ⁇ 8 to 500 8 kg body weight, more preferably 1.5 mg to 500 g Zkg body weight, even more preferably 1.5 mg to 200 g Zkg body weight, Even more preferably, 15 mg to 150 gZkg body weight, even more preferably 15 mg to: LOOgZkg body weight may be administered.
  • the active ingredient is an extract
  • the amount of the extract contained in the feed is expressed in terms of the dry weight of the original hon-shimeji. Say the value.
  • the dosage varies depending on various conditions, for example, the type of extraction solvent, the amount of solvent used, etc., so an amount smaller than the above dosage may be sufficient. Or beyond the scope.
  • the method for producing the feed of the present invention is not particularly limited, and if the formulation is similar to that of general feed, the prepared feed can contain the above-described antitumor agent of the present invention.
  • Yo The biological breeding agent may be produced, used, etc. according to the case of the feed.
  • Treatment of tumors in livestock, laboratory animals, poultry, pet animals, etc. by administering a feed comprising the antitumor agent of the present invention or immersing the target organism in a liquid containing an antitumor agent or Prevention can be done.
  • the present invention also provides a method for treating a tumor, comprising administering to a subject at least one selected from the group consisting of an effective amount of hon-shimeji mushroom and its treatment ability.
  • the subject is preferably a human being who requires antitumor action, and may be a cultured animal, a pet animal or the like as described above.
  • the effective amount means that when at least one (active ingredient) selected from the group consisting of hon-shimeji mushroom and its processed product is administered to the subject, the active ingredient is administered.
  • the specific effective amount is appropriately set according to the administration form, administration method, purpose of use and age, weight, symptom, etc. of the subject, but is preferably constant, as in the above-mentioned medicine.
  • the amount is 150 / zg to 1 kgZkg body weight per day for humans (eg adults), more preferably 150 / zg to 500 gZkg body weight.
  • At least one selected from an effective amount of hon-shimeji mushroom and a group capable of treating the same may be administered to the subject as it is, or the medicament as described above. It may be administered as a food or feed. Also, there is no limitation on the administration method, and for example, it may be administered by oral administration, injection or the like, similar to the above-mentioned medicine.
  • the disease targeted for the pharmaceutical, food or feed of the present invention can be treated.
  • the effect of suppressing cancer treatment, progression, and metastasis is exhibited. Get.
  • the active ingredient used in the present invention does not show toxicity even when an effective amount for the expression of its action is administered to the organism.
  • acetic acid extracted from Honshimeji hot water extraction residue Toxicity is not observed even when the ethyl extract fraction is orally administered to lgZ mice on day Z.
  • tumor inhibitory activity is used as a term synonymous with antitumor activity.
  • Fresh hon-shimeji fruiting body (Hon-shimeji LaOl-27: cultivated in Takarano) 16. 7kg was dried by dry heat at 60 ° C for 2 days to obtain 1,377g of dried hon-shimeji.
  • the dried hon-shimeji was pulverized with a Warinda blender to prepare 1,365 g of hon-shimeji dry powder.
  • 500 g of dried hon-shimeji powder was suspended in 10 L of water, extracted by heating at 95 ° C. for 3 hours, left to stand for 1 hour, and centrifuged to obtain 8.9 L of extract and an extraction residue.
  • the extract was concentrated with an evaporator and then freeze-dried to prepare 243 g of Honshimeji hot water extract.
  • the extraction residue was lyophilized as it was to prepare 245 g of Honshimeji hot water extraction residue.
  • ICR mice (Japan SLC) purchased 5-week-old females and used them at 6-week-old.
  • Sarcoma-180 (hereinafter S-180) tumor cells were transplanted into the abdominal cavity of ICR mice to make ascites, and transplanted to another mouse every 7 days. After passage, ascites was collected on the 7th day, centrifuged and washed with phosphate buffer, suspended in the same buffer, and after counting the number of cells, adjusted to 5 ⁇ 10 7 ZmL. This 0.1 mL was transplanted subcutaneously into the right flank of ICR mice, and the size of the solid tumor 7 days later was measured. Mice were divided into groups so that the average tumor size was uniform in each group, with 10 mice per group.
  • the dried hon-shimeji powder was prepared by mixing the powder prepared in Example 1 with a normal powdered feed CE-2 (CLEA Japan) at a mixing ratio of 10% and giving it to mice.
  • the hot water extract and hot water extraction residue prepared in Example 1 were also lyophilized and powdered, and similarly mixed with powdered feed CE-2.
  • the dose was converted to Honshimeji fruit body powder and used to be equivalent to the case where 10% by volume of powder sample CE-2 was mixed.
  • the actual dose is about 15 gZkg Z days for mice administered with Honshimeji fruit body powder, and about 7.5 g / kg / day for mice administered with hot water extract and mice administered with hot water extraction residue.
  • the control group received only CE-2.
  • Tumor size is S— 1 Measurements were made 5 weeks after 80 transplants. In addition, the major and minor diameters of the tumor were measured, and the volume was calculated according to the following calculation formula for comparison.
  • Tumor volume (mm 3 ) (major axis) X m V 2
  • Tumor suppressive activity was calculated according to the following formula.
  • Tumor suppressive activity (%) (tumor volume in the control group, tumor volume in the hon-shimeji treated group) tumor volume in the Z control group X 100
  • Honshimeji fruit body powder 1 G% 1 8 9 1 ⁇ 4 2 8 2 8 .2 Hot water extract (equivalent to 10% fruit body powder) 7 3 9 ⁇ 1 7 4 7 1 .9 Hot water extraction residue ⁇ child (Equivalent powder 10%) 1 1 3 1 Sat 2 2 7 5 7 .0
  • Example 2 250 g of dried hon-shimeji fruiting body powder prepared in the same manner as in Example 1 was suspended in 5 L of water, extracted by heating at 95 ° C for 3 hours, allowed to stand overnight, and then centrifuged (4200 rpm, 30 minutes, 25 ° C). 624 g of residue was obtained. Ethyl acetate was added thereto until the total amount became 5 L, and the mixture was stirred at room temperature for 3 hours. The extract was obtained by suction filtration using No. 2 filter paper (manufactured by Advantech). This was concentrated under reduced pressure while heating at 40 ° C. to dryness to obtain 9.4 g of an extract. Saratoko was dissolved in 100% ethanol and then dried to repeat twice to remove ethyl acetate.
  • Example 2 SCR-180 was transplanted and ICR mice (Japan SLC) 1 week later were mixed with the cetyl acetate extract prepared in Example 3 in powdered feed CE-2.
  • the experiment was conducted with 10 animals per group.
  • the dose was converted to hon-shimeji fruiting body powder, and it was used so as to be equivalent to the case where 10% by volume was mixed with powder sample CE-2. Actual throw The dose is approximately 628 mg / kg / day.
  • the control group received only CE-2. Tumor size and tumor suppressive activity (%) were calculated in the same manner as in Example 2.
  • Honshime cultured in PGY agar plate medium composition: glucose 2.0%, peptone 0.2%, yeast extract 0.2%, KH PO 0.05%, MgSO ⁇ 7 ⁇ OO. 05%, Agarl. 5%
  • Example 5 The hon-shimeji mycelium obtained in Example 5 was dried at 60 ° C. for 6 days to obtain 160 g of mycelium powder. Suspended with 3.2 L of water and extracted at 95 ° C for 3 hours. 4200rp at 25 ° C Centrifugation was carried out for 30 minutes to separate the extract and the extraction residue. The hot water extract was concentrated under reduced pressure at 40 ° C. and then freeze-dried to obtain 100.lg of powder. As in Example 2, S-180 was transplanted and ICR mice (Japan SLC) were mixed with mycelium powder or hot water extract prepared here for powdered feed CE-2. Gave. The experiment was conducted with 10 animals per group.
  • the dose was converted to hon-shimeji mycelium powder so that it was equivalent to the powder sample CE-2 mixed with 10% by volume.
  • the actual dose is about 15 gZkgZ in mice administered with Honshimeji mycelium powder, and about 9 gZkgZ days in mice administered with Honshimeji mycelium hot water extract.
  • the control group received only CE-2.
  • Tumor size and tumor suppressive activity (%) were calculated in the same manner as in Example 2. The results are shown in Table 3.
  • an antitumor agent characterized by containing at least one selected from the group consisting of hon-shimeji mushroom and processed products thereof as an active ingredient.
  • the antitumor agent is useful as a medicament, food or feed for treating or preventing tumors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Sustainable Development (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention a pour objet un agent antitumoral caractérisé en ce qu’il contient, en tant que composant actif, au moins l’un des membres du groupe constitué par les Lyophyllum shimeji. La présente invention décrit également les produits fabriqués à partir de cet agent. Cet agent antitumoral a pour origine un champignon comestible, et présente donc un risque d'effets secondaire faible. Cet agent antitumoral peut être employé dans des médicaments ou des aliments humains ou animaux destinés au traitement thérapeutique ou prophylactique d’une tumeur.
PCT/JP2005/015664 2004-08-30 2005-08-29 Agent antitumoral Ceased WO2006025329A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006532676A JPWO2006025329A1 (ja) 2004-08-30 2005-08-29 抗腫瘍剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004249838 2004-08-30
JP2004-249838 2004-08-30

Publications (1)

Publication Number Publication Date
WO2006025329A1 true WO2006025329A1 (fr) 2006-03-09

Family

ID=35999983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/015664 Ceased WO2006025329A1 (fr) 2004-08-30 2005-08-29 Agent antitumoral

Country Status (2)

Country Link
JP (1) JPWO2006025329A1 (fr)
WO (1) WO2006025329A1 (fr)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAZUNO C.: "Lyophyllum aggregatum (Honshimeji) Tatotai no Kozo Kaiseki Oyobi Koshuyo Kassei ni Kansuru Kenkyu", THE JISSEN WOMEN'S UNIVERSITY KASEI GAKUBU KIYO, no. 18, 1981, pages 47 - 53, XP002998849 *
XIAO-TONG Y. ET AL: "The Quantification of (1, 3)-beta-glucan in edible and medicinal mushroom polysaccharides by using Limulus G test", JUNWU XITONG (MYCOSYSTEMA), vol. 22, no. 2, 2003, pages 296 - 302, XP002998850 *

Also Published As

Publication number Publication date
JPWO2006025329A1 (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
KR101761379B1 (ko) 다기능 신규 균주 락토바실러스 사케이 k040706 및 이의 배양 방법
KR20030069991A (ko) 항상성 유지제
JP2014223051A (ja) エルゴチオネインの製造方法
WO2004091642A1 (fr) Preventif ou remede contre l'arthrite
JP4410555B2 (ja) 治療剤
TWI239245B (en) Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention
JPWO2006093267A1 (ja) 免疫調節作用を有する発酵組成物
CN1791419A (zh) 治疗药物
CN1809369A (zh) 水芹科植物的提取物及其制备方法
JP3735292B2 (ja) ダイエット効果のある健康食品および製剤
WO2004075905A1 (fr) Agent de formation musculaire et agent de prevention et de soins en cas d'affaiblissement musculaire
JP4852683B2 (ja) 大麦を発酵に付したものを有効成分とする血管新生阻害の作用を有する組成物
US20120003262A1 (en) Anticancer health food containing phellinus linteus and vegetable worms
JPWO2008123417A1 (ja) 抗疲労剤
WO2004087657A1 (fr) Agent anti-obesite
WO2006025329A1 (fr) Agent antitumoral
JP7011347B2 (ja) ベータグルカンを有効成分とする二日酔い解消用組成物またはアルコール性肝疾患の予防、改善または治療用組成物
JP2004244396A (ja) ＴＮＦ−α産生抑制剤
CA2352459A1 (fr) Agents de potentialisation de l'immunoactivite des cellules .gamma..delta. contenant un extrait mycelien de shiitake
CN1674926A (zh) 治疗剂
JP2002187851A (ja) 糖尿病予防・改善剤及びそれを含む機能性食品
US20250332131A1 (en) Composition for activating nicotinamide phosphoribosyltransferase
JP4873605B2 (ja) 穀類由来の成分を有効成分とする血管新生阻害の作用を有する組成物
JP4104853B2 (ja) 肝機能保護剤または改善剤
JP2004290157A (ja) ハナビラタケ組成物および飲食品

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006532676

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase